University of Erlangen-Nuremberg
Also known as: Assistant Medical Director of the Dept. of Radiooncology | Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg | Dean University Hospital Erlangen | Department of Anesthesiology, University Hospital Erlangen | Department of Anesthesiology, University Hospital Erlangen, Germany | Department of Gynecology and Obstetrics, Erlangen University Hospital | Department of Medicine 1 - Gastroenterology, Pneumology and Endocrinology, University Clinic Erlangen, Germany | Department of Medicine 4, University of Erlangen-Nuernberg | Department of Nephrology and Hypertension, University of Erlangen-Nuremberg | Department of Radiotherapy University hospital of Erlangen | Dept. of Microbiology, University Hospital Erlangen, Germany | Dept. of Pediatric Nephrology, University Hospital Erlangen, Germany | Dept. of Radiation Therapy, University Hospital Erlangen | Dept. of Radiation Therapy, University of Erlangen, Germany | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | Friedrich-Alexander-Universität Erlangen-Nürnberg | Friedrich-Alexander-Universität Erlange-Nürnberg | Friedrich-Alexander University Erlangen-Nürnberg | Institute for Biomedicine of Aging | Institute for Pathology, Klinikum Bayreuth | Institute of Medical Physics, FAU Erlangen-Nürnberg, Germany | Institute of Medical Physics, Friedrich-Alexander University of Erlangen-Nürnberg | Institute of Medical Physics, University of Erlangen-Nürnberg, Germany | Medizinische Klinik I, University Hospital Erlangen | Microbiology Institute Clinical Microbiology Immunology and Hygiene University Clinic of Erlangen Germany | Pharmacy of the University Hospital Erlangen | Universitaet Erlangen | Universitaetsklinikum Erlangen | Universitätsklinikum Erlangen | Universitätsklinikum Erlangen, Strahlenklinik | University Clinic Erlangen, Clinical Trial Unit, Department of Internal Medicine 3, Rheumatology & Immunology | University Clinic Erlangen, Department of Internal Medicine 3, Rheumatology & Immunology | University clinic Erlangen-Nuernberg | University Erlangen-Nuremberg | University Erlangen Nuremberg Medical School | University Erlangen-Nürnberg | University Erlangen-Nürnberg Erlangen, Germany | University Hospital Erlangen | University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Clinical Immunology | University Hospital Erlangen Germany | University Hospital Erlangen, Pathology | University Hospital Erlangen, Radiation Oncology | University Hospital of Erlangen, Germany | University of Erlangen, Germany | University of Erlangen-Nuremberg, Department of Internal Medicine 3, Rheumatology & Immunology | University of Erlangen-Nuremberg, Medical Department 3 | University of Erlangen-Nurnberg | University of Erlangen-Nürnberg | University of Erlangen-Nürnberg, Department of Biology | University of Erlangen-Nürnberg Medical School | University of Erlangen-Nürnberg Medical School, Department of Neurology, Germany | University of Erlangen, Vascular Surgery
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2001Last known activity
Sep 11, 2024
Timeline
1740s
- Jan 1, 1742
University of Erlangen-Nuremberg— Founded
Drugs by trial phase (152 distinct, 110 trials)
Phase 4 (25 own, 0 via acquisition)
Phase 3 (64 own, 0 via acquisition)
Phase 2 (40 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Anemia, Aplastic
- Anorexia
- Anorexia Nervosa
- Anus Neoplasms
- Arthralgia
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Atherosclerosis
- Autoimmune Diseases
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Squamous Cell
- Cardiovascular Diseases
- Cerebral Infarction
- Colitis
- Colitis, Ulcerative
- Communicable Diseases
- Corneal Endothelial Cell Loss
- Crohn Disease
- Dementia
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Dissociative Disorders
- Dwarfism
- Essential Hypertension
- Fever
- Fuchs' Endothelial Dystrophy
- Gastritis
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Helicobacter Infections
- HIV Infections
- Hodgkin Disease
- Hypercholesterolemia
- Hypertension
- Infections
- Inflammation
- Ischemia
- Kidney Diseases
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Major Depressive Disorder
- Melanoma
- Metabolic Syndrome
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Nephritis
- Osteoarthritis
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Pancreatic Neoplasms
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Postoperative Pain
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Psoriasis
- Rectal Neoplasms
- Renal Insufficiency, Chronic
- Retinal Detachment
- Schizophrenia
- Squamous Cell Carcinoma of Head and Neck
- Stroke
- Syndrome
- Ulcer
- Uveal Neoplasms
- Vitreoretinopathy, Proliferative
Recent trials (50)
- NCT06831981CollaboratorN/ASep 11, 2024
- NCT06244758Lead sponsorPhase 3Jan 18, 2024
- NCT06244758OfficialPhase 3Jan 18, 2024
- NCT05880524CollaboratorPhase 2Dec 31, 2023
- NCT06560801Lead sponsorPhase 4Jul 28, 2023
- NCT06560801Sponsor investigatorPhase 4Jul 28, 2023
- NCT06347718OfficialPhase 1/Phase 2Jul 17, 2023
- NCT06347718Lead sponsorPhase 1/Phase 2Jul 17, 2023
- NCT06347718Sponsor investigatorPhase 1/Phase 2Jul 17, 2023
- NCT05570409CollaboratorPhase 2/Phase 3Nov 3, 2022
- NCT05433116OfficialPhase 2Oct 31, 2022
- NCT05433116OfficialPhase 2Oct 31, 2022
- NCT05452213Study chairPhase 4Aug 31, 2022
- NCT05303857Lead sponsorPhase 4Mar 3, 2022
- NCT05303857Reponsible party - principal investigatorPhase 4Mar 3, 2022
Details
- Founded
- Bayreuth, DE Jan 1, 1742
- Last known activity
- Sep 11, 2024